Cancer Discov. 2016 Feb;6(2):113-4. doi: 10.1158/2159-8290.CD-NB2015-180. Epub 2015 Dec 23.
Results from an international phase II study show that the investigational BCL2 inhibitor venetoclax is effective in patients with chronic lymphocytic leukemia and the chromosome 17p deletion, whose prognosis is particularly poor. Venetoclax yielded high and durable responses in this population, including several complete remissions.
一项国际 II 期研究结果表明，研究用 BCL2 抑制剂 venetoclax 对伴有 17p 染色体缺失的慢性淋巴细胞白血病患者有效，这些患者的预后尤其差。venetoclax 在该人群中产生了高且持久的应答，包括数例完全缓解。
